Siam Bioscience

For the past 15 years, Siam Bioscience has established as a leading biopharmaceutical company in ASEAN for R&D, manufacturing, and commercialization. We have successfully brought products both from development of our own pipeline and technology transfer from partners to locally manufacture, commercialize, and supply in the ASEAN region. Those products are biotherapeutics, vaccines, and small molecules. Our strength in manufacturing and commercialization is evidenced by + Our EU GMP certified manufacturing plant for sterile injectable biopharmaceutical products + Our track records of successful technology transfer for local manufacturing and supply partners for multinational companies from Europe and U.S. + Our capability to manufacture both biological drug substance and drug products + Our position as market leader for most of the products we launched in Thailand. We still continue to grow our pipeline for biopharmaceuticals, vaccines, and small molecule and to expand our market for our existing products in other territories. The next phase of Siam Bioscience is to expand to new modalities of medicines, particularly cell and gene therapy, ATMP, oligonucleotides, bispecific monoclonal antibodies, and antibody-drug conjugates (ADCs). Our aim is to make these products accessible to patients in Thailand, ASEAN, and the vicinities via technology transfer for local manufacturing (localization) and/or direct supply from the partners. These efforts align with our goal to bring better healthcare for patients in Thailand, ASEAN, and beyond.